Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
The hypothesis of this study is that paclitaxel levels increase chromosomal instability (CIN) in tumors and this is lethal to tumors that have pre-existing CIN. Treatment will be administered on an outpatient basis. Paclitaxel will be initiated as standard infusions on days 1, 8, and 15 of a 21-day cycle. Participants will continue with paclitaxel for cycles 2-4 prior to surgery.
Full description
Primary Objectives
Secondary Objectives
Initial Actual Primary and Study Completion Date registered as 8/16/2022 with 24 participants enrolled.
Per a Protocol Amendment dated 5/7/24, this study will re-open to enroll up to 50 participants. NCI funding and data sharing information added.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
50 participants in 1 patient group
Loading...
Central trial contact
Cancer Connect
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal